Effects of angiotensin-converting enzyme inhibitors on the about the concurrent use of angiotensin-converting entreatment of anemia with erythropoietin.
tensin II is reported to facilitate erythropoiesis [6, 7] and receiving both rHuEPO and ACE inhibitors. Because of the endogenous erythropoietin production [8] , ACE inhibidemographic differences between the two groups, a propensity tors may exacerbate anemia by reducing angiotensin II score was used to eliminate the influence of confounding factors levels. ACE inhibitors also increase plasma Ac-SDKP and to match the patient population in these two patient groups. Multiple regression analysis also was performed.
(N-acetyl-seryl-aspartyl-lysyl-proline) [9, 10] by preventResults. When the ⌬Hct values were compared directly being the degradation of Ac-SDKP by ACE [11] . Increased tween the two groups or were assessed by multiple regression plasma Ac-SDKP prevents the cycling of hematopoietic analysis, no effect of ACE inhibitors was observed (P ϭ 0.941 stem and progenitor cells [12, 13] . These mechanisms, and P ϭ 0.308, respectively). When the effects of ACE inhibihowever, may be bypassed or overcome by exogenous tors on the treatment of anemia with rHuEPO were analyzed in 329 patients extracted from each group by their propensity rHuEPO administration. score, ⌬Hct did not differ between the two groups (P ϭ 0.355).
While some clinical studies report worsening effects
Conclusions. These results suggest that ACE inhibitors have of ACE inhibitors on anemia treated with erythropoietin no effect on the rHuEPO treatment for anemia in hemodialysis [1] [2] [3] [4] [5] , other studies of hemodialysis patients have found patients who were treated with a relatively low dose of ACE no effect of ACE inhibitors [14] [15] [16] [17] . Consequently, there inhibitors and low-dose rHuEPO.
are no definitive conclusions reached on the role of ACE inhibitors during the treatment of anemia. Generally, the question has been examined with a limited sample Since renal anemia directly influences the quality of size and treatment condition both retrospectively and life (QOL), prognosis, and rehabilitation of patients into prospectively. A large clinical study is necessary to resociety, an effective treatment is critically important. Resolve the effects of ACE inhibitors on rHuEPO-depencombinant human erythropoietin (rHuEPO) has been introduced into the clinic and is currently used throughdent treatment of renal anemia. Our study presents data out the world to treat patients with anemia. While many from a large post-marketing survey that retrospectively investigations have confirmed the efficacy and safety of identified 2213 patients who met our selection criteria. rHuEPO treatment for renal anemia, there is concern We compared two groups of patients with renal anemia that was being treated with rHuEPO both with and without concurrent ACE inhibitor therapy. The analyses in-matched and compared after reducing the influence of demographics through the use of propensity scores. From the original group of 2213 patients entered into this study, 1884 (85.1%) patients were assigned to the medical institutions in Japan from January 1990 to December 1994. Data were collected retrospectively for analrHuEPO treatment group (subsequently referred to as the monotherapy group), and 329 (14.9%) patients were ysis from a 12-week period after initiation of the rHuEPO treatment.
assigned to the rHuEPO ϩ ACE inhibitors treatment group (combination therapy group). The ACE inhibitors Criteria for patient exclusion from the survey included: (1) the patient withdrew from ACE inhibitor therapy used by patients in this study were enalapril maleate in 113 patients (34.3%), captopril in 96 patients (29.2%), during the 12-week period; (2) the patient was not initially treated with rHuEPO; (3) the patient received and other preparations in 120 patients (36.5%; Table 1 ). blood transfusion during the 12-week period; or (4) any Effect of ACE inhibitors on ⌬Hct of nine variables (sex, age, body weight, history of dialysis, pretreatment hematocrit, rHuEPO dose, concomiSimple comparison between groups. When ⌬Hct measurements were compared between the two groups, there tant administration of an iron preparation, pretreatment serum iron concentration, or classification of underlying was an increase of 0.561% per week in the monotherapy group and 0.562% per week in the combination therapy diseases) was not available. From the original 3585 patients, 2213 were identified who could be included in this group (Table 2) , but this was not statistically different (P ϭ 0.941, 95% CI, Ϫ0.041 to 0.045% per week). A dianalysis.
rect comparison of the two groups may be biased by difStatistical methods ferences in the patient populations between the groups. The result may have underestimated the effects of ACE The patients were allocated into two groups for analysis. One group received rHuEPO and ACE inhibitors inhibitors on rHuEPO-dependent recovery from anemia. When the distribution of demographic data of pain combination and the other group received rHuEPO alone. Weekly incremental hematocrit (⌬Hct) values tients were compared between the two groups, statistically significant differences in sex (P ϭ 0.001), age (P Ͻ were calculated from the medical records of each patient and were compared between the two groups. The effects 0.001), body weight (P Ͻ 0.001), history of dialysis (P ϭ 0.045), iron preparation (P ϭ 0.018), and underlying of ACE inhibitors on the rHuEPO treatment of renal anemia were measured three ways: (1) The ⌬Hct values disease (P ϭ 0.003) were found (Table 3 ). There was no significant difference in the dose of rHuEPO (97.8 Ϯ were compared between the two groups; (2) ⌬Hct values were compared between the two groups after multiple 44.6 U/kg/week vs. 97.7 Ϯ 41.6 U/kg/week; dose was considered the most important influence on anemia), nor regression analysis using ⌬Hct as a response variable and using ACE inhibitors and patient demographics as in the pretreatment Hct values or serum iron concentrations between the two groups. predictor variables; and (3) ⌬Hct values were compared between the two groups of patients after matching for Multiple regression analysis. Since there were demographic differences in the two groups, we examined the propensity score to eliminate the influence of confounding demographic factors [18] .
influence of these differences on the recovery from anemia. The effects of ACE inhibitors on ⌬Hct were anaAll data were expressed as mean Ϯ SD. Nominal data were analyzed with the chi-square test, and metric data lyzed by a multiple regression analysis using ⌬Hct as a 
Comparison between matched groups. Since we did not control the treatment assignment in this survey, the ACE inhibitors and demographic data of patients as predictor variables (Table 4) . ACE inhibitors reduced groups may have differences in their observed covariates, which could lead to biased estimates of the treatment the rHuEPO-dependent ⌬Hct increase by 0.021% per week, but this was not statistically significant (P ϭ 0.308).
effects. The propensity score was defined as a conditional probability for the ACE inhibitor treatment to be afHowever, this regression model seemed inappropriate for statistical evaluation of data in this analysis, because fected by the given covariates. When the propensity score differed between groups, an accurate conclusion may both the regression coefficient for the whole multiple regression models was low (R 2 ϭ 0.2607) and there were not be drawn because of interference by the additional confounding factors. To eliminate the influence of concorrelations between some of the predictor variables (data not shown). To account for these problems better founding factors, methods such as matching patients between groups by propensity score or stratification of paand to conduct a model-independent analysis, the two groups were matched using a propensity score.
tients by propensity scores have been used in prior studies [19, 20] . Our study employed the former method. By analysis comprised a comparison of the weekly ⌬Hct matching patients in the two groups by propensity score, values within a 12-week study period in the monotherapy the variables were balanced between the groups, and group (rHuEPO treatment alone) and combination therinterference of confounding factors related to the demoapy group (rHuEPO with concurrent ACE inhibitor graphic data removed from our analysis. The propensity treatment) using three methods (Table 7) . scores for the monotherapy group (0.144) and the combi-A simple comparison indicated no statistical signifination therapy group (0.175) were calculated using nine cance between the two groups (P ϭ 0.941). However, variables. Using this method, there was a significant difsome significant differences between the two groups were ference in the score between the two groups (P Ͻ 0.001).
apparent when patient demographics were included that As expected after matching, no significant bias in the may confound this analysis. Therefore, a multiple regresdistribution of demographic data between the two groups sion analysis was conducted to eliminate the potentially was found (Table 5) .
confounding factors related to patient demographics.
A comparison of ⌬Hct values between two groups
Multiple regression analysis also showed no statistical after matching the scores found that ⌬Hct was 0.592% importance for the ACE inhibitors (P ϭ 0.308). Finally, per week for the monotherapy group and 0.562% per because of the biased distribution of patient demographweek for the combination therapy group (Table 6 ). The ics in the two groups, patients were matched in the two difference in ⌬Hct was not statistically significant (P ϭ groups by propensity score. This methodology elimi-0.355, 95% CI, Ϫ0.092 to 0.033% per week) between nated confounding factors that potentially distort the the two groups.
causal relationship between rHuEPO and ACE inhibitor treatments. When the patients were matched for propen-DISCUSSION sity score, the difference in ⌬Hct between the two groups was 0.029% per week, which was not statistically differThe effects of ACE inhibitors on rHuEPO treatment of renal anemia were evaluated in this analysis. The ent (P ϭ 0.355). Thus, we did not find a significant effect of ACE inhibitors on the rHuEPO treatment for renal received 150 mg/day; one patient received 100 mg/day, and 94 patients received less than 75 mg/day. Most of the anemia, using the three methods of comparison.
Eight different ACE inhibitors were used in our analypatients received a dose of 37.5 mg/day. Charytan et al also used a low dose ACE inhibitor (enalapril maleate, sis. Apart from captopril and lisinopril, the other drugs were prodrugs that are metabolized and converted into 11 Ϯ 10.7 mg/day) [14] compared with Albiter et al's study [3] , and concluded that ACE inhibitors did not their active form mainly in liver. Regardless of their metabolic pathway, no significant difference of the ⌬Hct affect the rHuEPO dose needed to treat anemia. Similar to ACE inhibitor dosage, the typical rHuEPO was observed among the patients treated with different ACE inhibitors. For instance, ⌬Hct of captopril was dose used in Japan is lower than in other countries. In the United States, the recommended range for a starting 0.540% and that of enalapril malate was 0.594%. The dose of ACE inhibitors used in this analysis was considdose of rHuEPO is 50 to 100 U/body weight three times per week with a suggested targeted hematocrit value of 30 ered relatively low compared to other studies [3-5, 16, 17] . For example, though a dose reduction in the initial to 36% [23] . In Japan, the recommendation for a starting dose of rHuEPO is 3000 U/body three times per week. daily dosage is required, the daily maintenance dose of enalapril maleate and captopril is 10 to 40 mg/day and The dose is reduced to 1500 U/body weight two to three times per week or 3000 U/body two times per week 50 to 450 mg/day, respectively, in Europe and the United States [21, 22] , while the recommended daily dose of when the hematocrit value reaches about 30%. These recommendations for rHuEPO dosage were used in this these drugs in Japan is 5 to 10 mg/day and 37.5 to 75 mg/day, respectively. In our analysis, only three patients survey.
Taken together, our analysis shows that low-dose ACE treated with enalapril maleate received 15 mg/day, and 110 patients received less than 10 mg/day. Most patients inhibitors do not have a negative effect on the correction of anemia when low dose rHuEPO treatment is used. received a dose of 5 mg/day. Additionally, 96 patients were treated with captopril at dosages ranging from 12.5
Our conclusions differ from earlier communications reporting that ACE inhibitors reduced the effectiveness to 150 mg/day in our analysis. In this group, one patient of rHuEPO treatments in renal anemia. Albitar et al nisms may be observed only when a high-dose ACE inhibitor is accompanied by a low dose rHuEPO. These showed that the dose of rHuEPO required to maintain a target hemoglobin concentration (Ͼ10 g/dL) was findings taken together allow us to speculate that the inhibitory effect of ACE inhibitors may be apparent only greater in the ACE inhibitor treatment group (138 Ϯ 10 U/kg/week) than in the control group (80 Ϯ 9 U/kg/ when high-dose ACE inhibitors and low-dose rHuEPO (or a low target hematocrit value) are administered toweek). Most patients received a high dose of enalapril gether to a hemodialysis patient ( Fig. 1 and Table 8 ). (20 mg/day) in their study [3] . Erturk et al reported that
Results from 2213 hemodialysis patients were obafter discontinuation of high-dose enalapril (10 to 40 mg/ tained, and we sought to eliminate confounding factors day), the patients' hematocrit increased from 26.3 Ϯ by matching patients by propensity score. We conclude 6.4% to 29.8 Ϯ 6.3% while decreasing the dose of that ACE inhibitors have no effect on the rHuEPO treatrHuEPO from 208.3 Ϯ 99.0 U/kg/week to 141.4 Ϯ 81.0 ment in hemodialysis patients in our analysis. This lack U/kg/week [4] . In both of these studies, the targeted of effect may be due to the relatively low dose of ACE hematocrit value was not high (about 30%), while the inhibitors and rHuEPO used in Japan. Our analysis could dose of ACE inhibitor used by patients was high. In not identify the doses of ACE inhibitors and rHuEPO other words, these studies showed that high-dose ACE that are critically important for the treatment of renal inhibitors exacerbated anemia when the rHuEPO dose anemia. Further investigations with wider ranges of ACE was low.
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